Cargando…

Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study

This study was a randomized, double-blind, placebo-controlled study to evaluate the safety and viral shedding of live attenuated influenza vaccine (LAIV) in Chinese healthy juveniles and adults. A total of 80 Eligible volunteers were divided into two age groups (≥18 and 3–17 years old). Volunteers w...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Shi, Nianmin, Xu, Na, Wang, Haibin, Zhao, Hui, Xu, Haidong, Liu, Dawei, Zhang, Zheng, Li, Shuping, Zhang, Junnan, Guo, Chunhui, Huo, Jinglei, Zhao, Menghan, Luo, Fengji, Yang, Liqing, Bai, Yunhua, Lu, Qiang, Zhang, Yusong, Zhong, Yi, Gao, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694757/
https://www.ncbi.nlm.nih.gov/pubmed/36366310
http://dx.doi.org/10.3390/vaccines10111796
_version_ 1784837884933570560
author Li, Li
Shi, Nianmin
Xu, Na
Wang, Haibin
Zhao, Hui
Xu, Haidong
Liu, Dawei
Zhang, Zheng
Li, Shuping
Zhang, Junnan
Guo, Chunhui
Huo, Jinglei
Zhao, Menghan
Luo, Fengji
Yang, Liqing
Bai, Yunhua
Lu, Qiang
Zhang, Yusong
Zhong, Yi
Gao, Wenhui
author_facet Li, Li
Shi, Nianmin
Xu, Na
Wang, Haibin
Zhao, Hui
Xu, Haidong
Liu, Dawei
Zhang, Zheng
Li, Shuping
Zhang, Junnan
Guo, Chunhui
Huo, Jinglei
Zhao, Menghan
Luo, Fengji
Yang, Liqing
Bai, Yunhua
Lu, Qiang
Zhang, Yusong
Zhong, Yi
Gao, Wenhui
author_sort Li, Li
collection PubMed
description This study was a randomized, double-blind, placebo-controlled study to evaluate the safety and viral shedding of live attenuated influenza vaccine (LAIV) in Chinese healthy juveniles and adults. A total of 80 Eligible volunteers were divided into two age groups (≥18 and 3–17 years old). Volunteers were randomly and equally assigned to the experimental group and placebo-controlled group by ratio of 3:1 in each age group. Vaccination was carried out in steps. Totally, 34 (56.67%) adverse events and 24 (40.00%) adverse reactions of the LAIV group were reported. Most adverse reactions were grade 1 and grade 2, and the incidence of adverse reactions that grade 3 was 5%. The most common local reaction was runny nose/nasal congestion (n = 4, 6.67%). And the most common general reaction was fever (n = 10, 16.67%). There were no statistically significant differences in the incidence of total adverse reactions, different grades of adverse reactions, and symptoms between the experimental group and placebo-controlled group. No severe adverse events were reported. Three subjects (5.00%) had been detected vaccine strains on the 3rd day after LAIV vaccination; one was type B and the other two were H3N2. Four subjects (6.67%) had been detected with vaccine strains on the 7th day after LAIV vaccination, all were H3N2. There were no subjects detected carrying the influenza virus on the 15th day after vaccination. There were no statistically significant differences in the positive rate of vaccine strains of influenza virus between the experimental group and placebo-controlled group. The vaccine was well tolerated and not associated with increased rates in adverse reactions or the occurrence of severe adverse events. Pathogenicity of shed vaccine virus to surrounding people was not observed. Thus, Phase Ⅱ study can be carried out as scheduled.
format Online
Article
Text
id pubmed-9694757
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96947572022-11-26 Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study Li, Li Shi, Nianmin Xu, Na Wang, Haibin Zhao, Hui Xu, Haidong Liu, Dawei Zhang, Zheng Li, Shuping Zhang, Junnan Guo, Chunhui Huo, Jinglei Zhao, Menghan Luo, Fengji Yang, Liqing Bai, Yunhua Lu, Qiang Zhang, Yusong Zhong, Yi Gao, Wenhui Vaccines (Basel) Article This study was a randomized, double-blind, placebo-controlled study to evaluate the safety and viral shedding of live attenuated influenza vaccine (LAIV) in Chinese healthy juveniles and adults. A total of 80 Eligible volunteers were divided into two age groups (≥18 and 3–17 years old). Volunteers were randomly and equally assigned to the experimental group and placebo-controlled group by ratio of 3:1 in each age group. Vaccination was carried out in steps. Totally, 34 (56.67%) adverse events and 24 (40.00%) adverse reactions of the LAIV group were reported. Most adverse reactions were grade 1 and grade 2, and the incidence of adverse reactions that grade 3 was 5%. The most common local reaction was runny nose/nasal congestion (n = 4, 6.67%). And the most common general reaction was fever (n = 10, 16.67%). There were no statistically significant differences in the incidence of total adverse reactions, different grades of adverse reactions, and symptoms between the experimental group and placebo-controlled group. No severe adverse events were reported. Three subjects (5.00%) had been detected vaccine strains on the 3rd day after LAIV vaccination; one was type B and the other two were H3N2. Four subjects (6.67%) had been detected with vaccine strains on the 7th day after LAIV vaccination, all were H3N2. There were no subjects detected carrying the influenza virus on the 15th day after vaccination. There were no statistically significant differences in the positive rate of vaccine strains of influenza virus between the experimental group and placebo-controlled group. The vaccine was well tolerated and not associated with increased rates in adverse reactions or the occurrence of severe adverse events. Pathogenicity of shed vaccine virus to surrounding people was not observed. Thus, Phase Ⅱ study can be carried out as scheduled. MDPI 2022-10-26 /pmc/articles/PMC9694757/ /pubmed/36366310 http://dx.doi.org/10.3390/vaccines10111796 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Li
Shi, Nianmin
Xu, Na
Wang, Haibin
Zhao, Hui
Xu, Haidong
Liu, Dawei
Zhang, Zheng
Li, Shuping
Zhang, Junnan
Guo, Chunhui
Huo, Jinglei
Zhao, Menghan
Luo, Fengji
Yang, Liqing
Bai, Yunhua
Lu, Qiang
Zhang, Yusong
Zhong, Yi
Gao, Wenhui
Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study
title Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study
title_full Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study
title_fullStr Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study
title_full_unstemmed Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study
title_short Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study
title_sort safety and viral shedding of live attenuated influenza vaccine (laiv) in chinese healthy juveniles and adults: a phase ⅰ randomized, double-blind, placebo-controlled study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694757/
https://www.ncbi.nlm.nih.gov/pubmed/36366310
http://dx.doi.org/10.3390/vaccines10111796
work_keys_str_mv AT lili safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT shinianmin safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT xuna safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT wanghaibin safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT zhaohui safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT xuhaidong safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT liudawei safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT zhangzheng safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT lishuping safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT zhangjunnan safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT guochunhui safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT huojinglei safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT zhaomenghan safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT luofengji safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT yangliqing safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT baiyunhua safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT luqiang safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT zhangyusong safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT zhongyi safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy
AT gaowenhui safetyandviralsheddingofliveattenuatedinfluenzavaccinelaivinchinesehealthyjuvenilesandadultsaphaseirandomizeddoubleblindplacebocontrolledstudy